Cytokinetics says Phase 3 ACACIA-HCM data show aficamten boosts exercise performance in non-obstructive HCM

By Public Technologies
  • Additional ACACIA-HCM trial analyses were presented at the HFSA Annual Scientific Meeting 2026, extending evidence for aficamten in non-obstructive HCM.
  • New exercise-performance analyses showed broader improvement versus placebo, aligning with better patient-reported health status and supportive biomarker trends.
  • A responder analysis indicated more patients on aficamten achieved meaningful overall clinical benefit across multiple domains than placebo.
  • Safety updates highlighted heart-failure events concentrated during early dose titration, supporting a titration approach guided by heart-pumping function monitoring.
  • Cytokinetics plans to file a supplemental New Drug Application with the FDA this quarter to expand aficamten’s label into non-obstructive HCM.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610121600PRIMZONEFULLFEED9844056) on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.